Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021

A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April–May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and am...

Descripción completa

Detalles Bibliográficos
Autores principales: Beser, Jessica, Galanis, Ilias, Enkirch, Theresa, Kühlmann Berenzon, Sharon, van Straten, Edward, Duracz, Jan, Rapp, Marie, Zakikhany, Katherina, Mansjö, Mikael, Wigren Byström, Julia, Forsell, Mattias N. E., Groenheit, Ramona, Tegmark Wisell, Karin, Bråve, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233662/
https://www.ncbi.nlm.nih.gov/pubmed/35752708
http://dx.doi.org/10.1038/s41598-022-15183-w
_version_ 1784735844313071616
author Beser, Jessica
Galanis, Ilias
Enkirch, Theresa
Kühlmann Berenzon, Sharon
van Straten, Edward
Duracz, Jan
Rapp, Marie
Zakikhany, Katherina
Mansjö, Mikael
Wigren Byström, Julia
Forsell, Mattias N. E.
Groenheit, Ramona
Tegmark Wisell, Karin
Bråve, Andreas
author_facet Beser, Jessica
Galanis, Ilias
Enkirch, Theresa
Kühlmann Berenzon, Sharon
van Straten, Edward
Duracz, Jan
Rapp, Marie
Zakikhany, Katherina
Mansjö, Mikael
Wigren Byström, Julia
Forsell, Mattias N. E.
Groenheit, Ramona
Tegmark Wisell, Karin
Bråve, Andreas
author_sort Beser, Jessica
collection PubMed
description A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April–May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and among non-vaccinated 20.1% had detectable levels of antibodies. We tested for differences in seroprevalence between age groups and by sex and estimated seroprevalence among previously infected participants by time since reporting.
format Online
Article
Text
id pubmed-9233662
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-92336622022-06-27 Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021 Beser, Jessica Galanis, Ilias Enkirch, Theresa Kühlmann Berenzon, Sharon van Straten, Edward Duracz, Jan Rapp, Marie Zakikhany, Katherina Mansjö, Mikael Wigren Byström, Julia Forsell, Mattias N. E. Groenheit, Ramona Tegmark Wisell, Karin Bråve, Andreas Sci Rep Article A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April–May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and among non-vaccinated 20.1% had detectable levels of antibodies. We tested for differences in seroprevalence between age groups and by sex and estimated seroprevalence among previously infected participants by time since reporting. Nature Publishing Group UK 2022-06-25 /pmc/articles/PMC9233662/ /pubmed/35752708 http://dx.doi.org/10.1038/s41598-022-15183-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Beser, Jessica
Galanis, Ilias
Enkirch, Theresa
Kühlmann Berenzon, Sharon
van Straten, Edward
Duracz, Jan
Rapp, Marie
Zakikhany, Katherina
Mansjö, Mikael
Wigren Byström, Julia
Forsell, Mattias N. E.
Groenheit, Ramona
Tegmark Wisell, Karin
Bråve, Andreas
Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021
title Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021
title_full Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021
title_fullStr Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021
title_full_unstemmed Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021
title_short Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021
title_sort seroprevalence of sars-cov-2 in sweden, april 26 to may 9, 2021
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233662/
https://www.ncbi.nlm.nih.gov/pubmed/35752708
http://dx.doi.org/10.1038/s41598-022-15183-w
work_keys_str_mv AT beserjessica seroprevalenceofsarscov2inswedenapril26tomay92021
AT galanisilias seroprevalenceofsarscov2inswedenapril26tomay92021
AT enkirchtheresa seroprevalenceofsarscov2inswedenapril26tomay92021
AT kuhlmannberenzonsharon seroprevalenceofsarscov2inswedenapril26tomay92021
AT vanstratenedward seroprevalenceofsarscov2inswedenapril26tomay92021
AT duraczjan seroprevalenceofsarscov2inswedenapril26tomay92021
AT rappmarie seroprevalenceofsarscov2inswedenapril26tomay92021
AT zakikhanykatherina seroprevalenceofsarscov2inswedenapril26tomay92021
AT mansjomikael seroprevalenceofsarscov2inswedenapril26tomay92021
AT wigrenbystromjulia seroprevalenceofsarscov2inswedenapril26tomay92021
AT forsellmattiasne seroprevalenceofsarscov2inswedenapril26tomay92021
AT groenheitramona seroprevalenceofsarscov2inswedenapril26tomay92021
AT tegmarkwisellkarin seroprevalenceofsarscov2inswedenapril26tomay92021
AT braveandreas seroprevalenceofsarscov2inswedenapril26tomay92021

Ejemplares similares